Immunology and Microbiology
Graft-Versus-Host Disease
100%
T Cell
79%
Tacrolimus
56%
Chronic Graft Versus Host Disease
47%
Hematopoietic Stem Cell Transplantation
42%
Acute Graft Versus Host Disease
41%
Mycophenolic Acid
40%
Anti-Thymocyte Globulin
38%
Adoptive Immunotherapy
38%
Stem Cell Transplant
38%
Stem Cell
36%
Transplant Procedure
36%
Cell Transplantation
34%
Overall Survival
32%
Cyclophosphamide
28%
Multiple Myeloma
27%
Drug Megadose
26%
Plerixafor
26%
Stem Cell Transplantation
25%
CD20
25%
Sirolimus
25%
Allogeneic Hematopoietic Stem Cell Transplantation
24%
Bispecific Antibody
23%
Hematopoietic Cell
21%
CD34
18%
Peripheral Blood Stem Cell
17%
Cytokine
16%
Granulocyte Colony-Stimulating Factor
16%
Methotrexate
15%
CD3 Antigen
15%
Autologous Stem Cell Transplantation
15%
CD19
14%
Human Immunodeficiency Virus Infection
14%
Myeloid
14%
Tumor Cell
13%
Myeloid-Derived Suppressor Cell
12%
Immunotherapy
12%
Upregulation
12%
CTLA-4
12%
Cytomegalovirus
12%
Phospholipid Antibody
12%
Gemtuzumab Ozogamicin
12%
Dormancy
12%
Hemocyte
12%
Antiphospholipid Syndrome
12%
Allotransplantation
12%
Conditioning
12%
Hematopoietic Stem Cell
12%
Immunocompetent Cell
12%
Human Immunodeficiency Virus
12%
Medicine and Dentistry
Overall Survival
83%
Acute Myeloid Leukemia
76%
Graft Versus Host Reaction
63%
Multiple Myeloma
51%
Melphalan
51%
Stem Cell Transplant
45%
Autologous Stem Cell Transplantation
38%
T Cell
38%
Clinical Trial
30%
Transplantation
29%
Drug Megadose
27%
Cell Transplantation
27%
Hematopoietic Stem Cell
27%
Mycophenolic Acid
25%
Phase I Trials
25%
Cytoprotection
25%
Adoptive Immunotherapy
25%
Palifermin
25%
Hematopoietic Stem Cell Transplantation
22%
Cancer
19%
Stem Cell
19%
Charlson Comorbidity Index
19%
Disease
19%
Acute Graft Versus Host Disease
18%
Hematologic Malignancy
18%
Conditioning
17%
Bispecific Antibody
17%
Malignant Neoplasm
16%
Hematopoietic Stem Cell
16%
Cyclosporine
16%
Human Immunodeficiency Virus Infection
14%
Hazard Ratio
14%
Plerixafor
13%
Granulocyte Colony Stimulating Factor
13%
Cell Therapy
12%
Myeloid-Derived Suppressor Cell
12%
Pericardial Fluid
12%
Eaton Lambert Syndrome
12%
Geriatric Assessment
12%
Gastroenteritis
12%
Lenalidomide
12%
Graft Rejection
12%
Gemtuzumab Ozogamicin
12%
Bortezomib
12%
Cytomegalovirus
12%
Metastatic Carcinoma
12%
Dormancy
12%
Creatinine Clearance
12%
Myeloma
12%
Antiphospholipid Syndrome
12%
Keyphrases
Graft-versus-host Disease (GvHD)
85%
Acute Myeloid Leukemia
63%
Overall Survival
62%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
62%
Mycophenolate Mofetil
38%
Tacrolimus
31%
Older Adults
25%
Antithymocyte Globulin
25%
Older Patients
25%
Phase I Trial
25%
Newly Diagnosed
25%
Gastrointestinal Graft-versus-host Disease
25%
Graft-versus-host Disease Prophylaxis
22%
Unrelated Hematopoietic Stem Cell Transplantation
21%
Dose-limiting Toxicity
19%
Charlson Comorbidity Index
19%
Cyclosporine
18%
Chemotherapy
18%
Multiple Myeloma
17%
Confidence Interval
17%
Unrelated Donor
17%
Severe Acute
17%
Melphalan
17%
Unrelated Donor Transplantation
16%
Large Cohort
15%
High-dose Melphalan
15%
Risk Factors
14%
Non-relapse Mortality
14%
Cumulative Incidence
13%
Induction Chemotherapy
12%
Therapy Selection
12%
Amyloidoma
12%
Conditioning Regimen
12%
Lambert-Eaton Syndrome
12%
Lung Large Cell Neuroendocrine Carcinoma (L-LCNEC)
12%
Early Mortality
12%
Cytomegalovirus
12%
Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
12%
Geriatric Assessment
12%
High Incidence
12%
Melphalan Conditioning
12%
Cytomegalovirus Viremia
12%
Sirolimus
12%
Allogeneic Transplantation
12%
Epidermal Growth Receptor
12%
Prostate Cancer Vaccine
12%
Gemtuzumab Ozogamicin
12%
Blood Lymphocyte Count
12%
Risk Outcomes
12%
Non-absorbable
12%